134 related articles for article (PubMed ID: 22720254)
1. STATing the importance of immune modulation by platinum chemotherapeutics.
Hato SV; de Vries IJ; Lesterhuis WJ
Oncoimmunology; 2012 Mar; 1(2):234-236. PubMed ID: 22720254
[TBL] [Abstract][Full Text] [Related]
2. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.
Lesterhuis WJ; Punt CJ; Hato SV; Eleveld-Trancikova D; Jansen BJ; Nierkens S; Schreibelt G; de Boer A; Van Herpen CM; Kaanders JH; van Krieken JH; Adema GJ; Figdor CG; de Vries IJ
J Clin Invest; 2011 Aug; 121(8):3100-8. PubMed ID: 21765211
[TBL] [Abstract][Full Text] [Related]
3. STAT Family Protein Expression and Phosphorylation State during moDC Development Is Altered by Platinum-Based Chemotherapeutics.
de Haas N; de Koning C; di Blasio S; Flórez-Grau G; de Vries IJM; Hato SV
J Immunol Res; 2019; 2019():7458238. PubMed ID: 31309123
[TBL] [Abstract][Full Text] [Related]
4. Pro-inflammatory chitosan/poly(γ-glutamic acid) nanoparticles modulate human antigen-presenting cells phenotype and revert their pro-invasive capacity.
Castro F; Pinto ML; Silva AM; Pereira CL; Teixeira GQ; Gomez-Lazaro M; Santos SG; Barbosa MA; Gonçalves RM; Oliveira MJ
Acta Biomater; 2017 Nov; 63():96-109. PubMed ID: 28919508
[TBL] [Abstract][Full Text] [Related]
5. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
[TBL] [Abstract][Full Text] [Related]
6. Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2.
Huber S; Hoffmann R; Muskens F; Voehringer D
Blood; 2010 Oct; 116(17):3311-20. PubMed ID: 20625006
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of Programmed Death Ligand 2 on Hepatitis C Virus Infected Hepatocytes by Calcineurin Inhibitors.
Koike K; Takaki A; Yagi T; Iwasaki Y; Yasunaka T; Sadamori H; Shinoura S; Umeda Y; Yoshida R; Sato D; Nobuoka D; Utsumi M; Miyake Y; Ikeda F; Shiraha H; Fujiwara T; Yamamoto K
Transplantation; 2015 Jul; 99(7):1447-54. PubMed ID: 25675203
[TBL] [Abstract][Full Text] [Related]
8. Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death.
Di Blasio S; Wortel IM; van Bladel DA; de Vries LE; Duiveman-de Boer T; Worah K; de Haas N; Buschow SI; de Vries IJ; Figdor CG; Hato SV
Oncoimmunology; 2016 Aug; 5(8):e1192739. PubMed ID: 27622063
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in platinum-based chemotherapeutics that exhibit inhibitory and targeted mechanisms of action.
Khoury A; Deo KM; Aldrich-Wright JR
J Inorg Biochem; 2020 Jun; 207():111070. PubMed ID: 32299045
[TBL] [Abstract][Full Text] [Related]
10. Dexamethasone counteracts the immunostimulatory effects of triiodothyronine (T3) on dendritic cells.
Montesinos MM; Alamino VA; Mascanfroni ID; Susperreguy S; Gigena N; Masini-Repiso AM; Rabinovich GA; Pellizas CG
Steroids; 2012 Jan; 77(1-2):67-76. PubMed ID: 22056479
[TBL] [Abstract][Full Text] [Related]
11. Novel immunomodulatory effects of adiponectin on dendritic cell functions.
Tsang JY; Li D; Ho D; Peng J; Xu A; Lamb J; Chen Y; Tam PK
Int Immunopharmacol; 2011 May; 11(5):604-9. PubMed ID: 21094289
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics.
Hato SV; Khong A; de Vries IJ; Lesterhuis WJ
Clin Cancer Res; 2014 Jun; 20(11):2831-7. PubMed ID: 24879823
[TBL] [Abstract][Full Text] [Related]
13. The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues.
Tel J; Hato SV; Torensma R; Buschow SI; Figdor CG; Lesterhuis WJ; de Vries IJ
Cancer Immunol Immunother; 2012 Jul; 61(7):1101-11. PubMed ID: 22193989
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and immunomodulatory effects of the human chondrocytes, hChonJ.
Lim CL; Lee YJ; Cho JH; Choi H; Lee B; Lee MC; Kim S
BMC Musculoskelet Disord; 2017 May; 18(1):199. PubMed ID: 28521800
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors.
Hammond E; Haynes NM; Cullinane C; Brennan TV; Bampton D; Handley P; Karoli T; Lanksheer F; Lin L; Yang Y; Dredge K
J Immunother Cancer; 2018 Jun; 6(1):54. PubMed ID: 29898788
[TBL] [Abstract][Full Text] [Related]
16. Platinum-Based Nanovectors Engineered with Immuno-Modulating Adjuvant for Inhibiting Tumor growth and Promoting Immunity.
Liu L; Chen Q; Ruan C; Chen X; Zhang Y; He X; Zhang Y; Lu Y; Guo Q; Sun T; Wang H; Jiang C
Theranostics; 2018; 8(11):2974-2987. PubMed ID: 29896297
[TBL] [Abstract][Full Text] [Related]
17. T cell recruitment triggered by optimal dose platinum compounds contributes to the therapeutic efficacy of sequential PD-1 blockade in a mouse model of colon cancer.
Fu D; Wu J; Lai J; Liu Y; Zhou L; Chen L; Zhang Q
Am J Cancer Res; 2020; 10(2):473-490. PubMed ID: 32195021
[TBL] [Abstract][Full Text] [Related]
18. Platinum-based chemotherapy: gastrointestinal immunomodulation and enteric nervous system toxicity.
Stojanovska V; Sakkal S; Nurgali K
Am J Physiol Gastrointest Liver Physiol; 2015 Feb; 308(4):G223-32. PubMed ID: 25501548
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal Stem Cells Upregulate the Expression of PD-L1 But Not VDR in Dendritic Cells.
Moravej A; Karimi MH; Geramizadeh B; Azarpira N; Zarnani AH; Yaghobi R; Khosravi M; Kalani M; Gharesi-Fard B
Immunol Invest; 2017 Jan; 46(1):80-96. PubMed ID: 27736253
[TBL] [Abstract][Full Text] [Related]
20. Platinum anticancer agents and antidepressants: desipramine enhances platinum-based cytotoxicity in human colon cancer cells.
Kabolizadeh P; Engelmann BJ; Pullen N; Stewart JK; Ryan JJ; Farrell NP
J Biol Inorg Chem; 2012 Jan; 17(1):123-32. PubMed ID: 21918844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
